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Abstract
Activation of the Wnt/b-catenin pathway has been observed in at least 1/3 of hepatocellular carcinomas (HCC), and a
significant number of these have mutations in the b-catenin gene. Therefore, effective inhibition of this pathway could
provide a novel method to treat HCC. The purposed of this study was to determine whether FH535, which was previously
shown to block the b-catenin pathway, could inhibit b-catenin activation of target genes and inhibit proliferation of Liver
Cancer Stem Cells (LCSC) and HCC cell lines. Using b-catenin responsive reporter genes, our data indicates that FH535 can
inhibit target gene activation by endogenous and exogenously expressed b-catenin, including the constitutively active form
of b-catenin that contains a Serine37Alanine mutation. Our data also indicate that proliferation of LCSC and HCC lines is
inhibited by FH535 in a dose-dependent manner, and that this correlates with a decrease in the percentage of cells in S
phase. Finally, we also show that expression of two well-characterized targets of b-catenin, Cyclin D1 and Survivin, is
reduced by FH535. Taken together, this data indicates that FH535 has potential therapeutic value in treatment of liver
cancer. Importantly, these results suggest that this therapy may be effective at several levels by targeting both HCC and
LCSC.
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Introduction
Hepatocellular carcinoma (HCC), the most common liver
cancer, is the fifth most common cancer and the third highest
cause of cancer-related mortality worldwide [1–2]. The alarming
rise in HCC incidence in Europe and North America in recent
years is related mainly to hepatitis C virus infection, although
other factors such as excessive alcohol consumption and obesity
also contribute to this increase [3]. The etiology of HCC is
complex and involves numerous genetic and epigenetic alterations
and the disruption of various signaling pathways including the
Wnt/b-catenin, Ras/Raf/MAPK, PI3K/AKT/mTOR, HGF/c-
MET, IGF, VEGF and PDGF pathways. Among these, the Wnt/
b-catenin pathway is considered among the most difficult to inhibit
[4]. Currently, few chemical agents targeting the Wnt/b-catenin
pathway are available or under investigation [5].
Activation of the canonical Wnt/b-catenin pathway involves the
binding of Wnt proteins to cell surface Frizzled receptors and
LRP5/6 co-receptors. In the absence of Wnt proteins, much of the
cellular b-catenin is bound to E-cadherin on the cell membrane.
Cytosolic b-catenin is constitutively phosphorylated at specific
serine residues by an enzymatic complex that includes adenoma-
tous polyposis coli (APC), Axin, and the kinases glycogen synthase
kinase-3b (GSK-3b) and casein kinase I, marking it for ubiquitin-
mediated proteolysis. Under these conditions, the TCF/LEF
transcription factors are bound to their cognate DNA recognition
elements along with members of the Groucho family of co-
repressors, insuring the transcriptional silencing of b-catenin target
genes. Engagement of Wnt proteins with the Frizzled receptor
activates the Dishevelled protein, resulting in the dissociation of
the cytosolic destructive complex and inhibition of GSK-3b. This
leads to the stabilization and accumulation of cytoplasmic b-
catenin, which then enters the nucleus, binds TCF/LEF proteins
and leads to the subsequent dissociation of groucho co-repressors,
recruitment of the coactivator p300 and activation of b-catenin
target genes [6–9]. Many of the b-catenin targets, including Cyclin
D1, c-myc and Survivin, promote cell cycle progression and
inhibit apoptosis [10–12]. Consistent with this data, activation of
the Wnt/b-catenin pathway is seen in a variety of cancers,
including HCC. Aberrant activation of the Wnt/b-catenin
pathway has been observed in at least 1/3 of HCC, and roughly
20% of HCCs have mutations in the b-catenin gene. More than
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50% of HCC tumors display nuclear accumulation of b-catenin
indicating that other factors may be involved such as aberrant
methylation of the tumor suppressors APC and E-cadherin,
inactivation of casein kinase and GSK-3b, or increased secretion
of Wnt ligants [4–5].
There has been increasing interest in the role of liver cancer
stem cells (LCSC) in tumorigenesis, tumor progression, invasion
and metastases. The cancer stem cell theory suggests that a tumor
is comprised of a heterogeneous population of cells that form a
distinct cellular hierarchy. Recent studies have provided convinc-
ing evidence that these cells do exist in solid tumors of many types
including, brain, breast, colorectal, liver, pancreas and prostate
cancers. In 2006, two different groups isolated a CD133+
subpopulation from HCC cell lines and described higher
proliferative and tumorigenic potential, consistent with stem cell
properties. CD44 was also found as an important marker used in
combination with other stem cell markers to better define the
surface phenotype of LCSC. It has been demonstrated that
CD133+ and CD90+ cells co-expressing CD44+ are more
aggressive than those expressing CD133 or CD90 alone [13–14].
The chemical agents used to target Wnt-/b-catenin pathway are
at the membrane, cytosol and transcription factor levels [5]. The
small molecular agent FH535 is a dual inhibitor of peroxisome
proliferator-activated receptor (PPAR) and b-catenin/TCF/LEF.
FH535 has been shown to inhibit proliferation of HCC and
hepatoblastoma cell lines and its specificity on inhibition of b-
catenin/TCF/LEF activity was illustrated in hepatoblastoma cell
line HepG2 [15].
The aim of this study was to determine if FH535 can inhibit the
activation of b-catenin-regulated genes by endogenous and
ectopically expressed b-catenin in the HCC cell lines Huh7,
Hep3B and PLC and liver cancer stem cells (LCSC). The
specificity of FH535 on inhibition of b-catenin via TCF/LEF
activation was assayed in dual luciferase reporter transfected in
LCSC and in HCC cells. Proliferation, cell cycle, and other
targeted genes and proteins were assayed.
Materials and Methods
2.1 Cell culture
The HCC cell line Huh7 [16] was a gift from Dr. Guangxiang
Luo (University of Alabama – Birmingham). The HCC cell lines
Hep3B and PLC were purchased from American Type Culture
Collection (ATCC; Manassas, VA, USA). Hep3B and PLC both
express HBV surface antigen, and Huh7 express hepatitis delta
antigen. The Hep3B is p53 negative, the PLC has reduced p53
expression, and Huh7 has increased p53 protein level [17–18].
These cell lines were cultured in Dulbecco’s Modified Eagles
Medium (DMEM; Invitrogen, Carlsbad, CA, USA) supplemented
with 10% fetal bovine serum (FBS), glutamine and penicillin/
streptomycin. The liver cancer stem cells (LCSC; Catalog #
36116-43, CelProgen, San Pedro, CA, USA) were expanded up to
and used within the first 4 passages in CelProgen complete growth
media with 10% FBS in extra-cellular matrix (ECM) coated flasks
(CelProgen). Flow cytometry profile and tumorigenicity of the
LCSC are shown in Figures S1 and S2. Other cell lines were
cultured in standard plastic wares without ECM coating. Cells
were cultured in NuAire incubator (Plymouth, MI, USA) at 37uC
with 5% CO2.
2.2 Chemicals
FH535, XAV939 and LiCl were purchased from Sigma-Aldrich
(St. Louis, MO, USA). Methyl-3H-thymidine (2 Ci/mM) was from
MP Biomedicals (Costa Mesa, CA, USA). The X-Treme Gene 9
and Turbofect transfection reagents were from Roche (Indianap-
olis, IN, USA) and Thermo Scientific (Waltham, MA, USA),
respectively. The propidium iodide-based cell cycle analysis kit was
from GenScript (Piscataway, NJ, USA). All the other chemicals
were from Sigma-Aldrich (St. Louis, MO, USA).
2.3 Plasmids
The TOPFlash luciferase reporter gene, which contains 3 copies
of a TCF/LEF binding site, and FOPFlash luciferase reporter,
identical to TOPFlash except the TCF/LEF sites have been
mutated, were purchased from Addgene (Cambridge, MA, USA)
[19]. The pRL renilla luciferase vector was from Promega
(Madison, WI, USA). Expression vectors for wild-type b-catenin
and bCatS37A were provided by S. Byers [20] and E3-pGL3,
containing mouse alpha-fetoprotein enhancer E3 fused to pGL3-
promoter, was described previously [21].
2.4 3H-thymidine incorporation assay
This assay was performed as described previously by our
published method and by other researchers [22–24]. Briefly, cells
were seeded in 96 well plates at 1,000–5000 cell/well in 0.2 ml
DMEM +10%FBS and treated in duplicate with different
concentrations of FH535 for 72 h. The cells were pulsed with
3H-thymidine at 1 mCi/well for 4 h. Alternatively, cells were
cultured at 2500 cells/well in 0.1 ml of medium for 24 h, followed
by the simultaneous addition of FH535 (0–15 mM) and 3H-
thymidine (1 mCi/well) to a final volume of 0.2 ml/well., followed
by incubation for an additional 18 hours. In both situations, at the
end of incubation, cells were washed and fixed in 0.3 ml of 10%
trichloroacetic acid (TCA) for 12 min. After aspiration of TCA,
the cells were lysed in 0.2 M NaOH/0.2% SDS for 40 min. 3H-
thymidine incorporation was measured by scintillation counting in
a Packard Scintillation Analyzer (Covina, CA, USA). We did not
perform MTT assay for cell proliferation to compare with 3H-
thymidine incorporation because there is color reaction between
FH535 and the MTT assay reagent (thiazolyl blue tetrazolium
bromide). The concentration of FH535 to cause a 50% inhibition
of cell grown (IC50) was determined by the following method. No-
drug data was used as 100% at the Y-axis, and from this a 50%
inhibition on the Y-axis was determined. From the 50% value
point, we draw a parallel line to the X-axis (the drug concentration
axis) to identify the cross point on the concentration curve. From
the cross point we draw a parallel line to the Y-axis, and find the
cross point on the X-axis. This cross point on the X-axis is the
IC50 point. All experiments were performed at least twice.
2.5 Transient Transfections and Dual Luciferase Assays
For transfections, Huh7, PLC and LCSC were plated at
36105 cells/well in 1 ml culture medium in 12 well plates; after
24 h, cells were co-transfected with TOPFlash/pRL vectors (DNA
ratio 10:1) or FOPFlash/pRL vectors (DNA ratio 10:1) using X-
treme Gene 9 (Roche, Indianapolis, IN, USA) transfection reagent
following manufacturer’s instruction. After 6 h, the medium was
aspirated and cells were added with 1 ml of culture media
containing different concentrations of FH535, DMSO alone
(vehicle), and/or 10 mM LiCl. In all cases, the final concentration
of DMSO was 0.08%. The amount of vehicle DMSO was held
constant in drug treatments and the final concentration of DMSO
in each treatment was the same and was designed to less than
0.1%. After 36 h, dual luciferase assays were done with the
Promega Dual Luciferase Assay System (Madison, WI, USA)
according to manufacturer’s protocols. Luciferase activity was
measured in the Lumat LB 9507 luminometer (Berthold
Technologies, Oak Ridge, TN, USA). Briefly, the cells were
Wnt/b-Catenin Signaling Pathway in HCC
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washed once with sterile PBS, and lysed in 16 lysis buffer
(Promega) (0.25 ml/well) for 15 min at room temperature. Ten ml
of crude cell lysate (prepared according to Promega Protocol) was
added to 50 ml of luciferase assay LARII substrate in a 12675 mm
polystyrene tube (Fisher Scientific, Pittsburgh, PA, USA) to
measure the firefly luciferase activity, followed by addition of
50 ml of Stop and Glo substrate to measure the Renilla luciferase
activity. The measured Renilla luciferase activity was used to
normalize the measured firefly luciferase activity.
For co-transfections with b-catenin expression vectors, cells
were plated at 16105 cells/well in 24-well plates. Cells were
transfected with 340 ng Luciferase reporter plasmid, 170 ng b-
catenin expression plasmid, and 10 ng pRL/well using the
Turbofect transfection reagent (Pittsburg, PA, USA). After 5-6 h,
FH535 (or DMSO vehicle control) was added. After an additional
36 h, cell extracts (prepared according to Promega protocol) were
prepared and used immediately or stored at 280uC. All
transfections were performed in duplicate and repeated at least
two times. Luciferase assays were performed with cell extracts
using the Dual Luciferase Assay System (Promega, Madison, WI,
USA) according to manufacturer’s protocols. Luciferase activity
was measured in duplicate.
2.6 Cell cycle analysis
Huh7 cells were cultured in DMEM +10% FBS for 24 h. The
cells were washed with serum free DMEM 3 times, then cultured
in DMEM +0.1% FBS for 24 h for synchronization of the cells.
The cells were then cultured in DMEM+10% FBS with different
concentrations of FH535 for 24 h. The cells were harvested and
stained with propidium iodide (PI) and analyzed by flow cytometry
according to the GenScript protocol. LCSC were cultured in
CelProgen complete growth medium and treated the same way as
indicated above.
2.7 RT-PCR and Western analysis
RT-PCR. Cells were cultured in DMEM+10% FBS in
100 mm tissue culture dishes until ,70% confluence and then
treated with DMSO alone or increasing concentrations of FH535
in DMSO for 38 h. For RNA analysis, cells were harvested and
cDNA was prepared as described [21]. Quantitative PCR was
carried out with SYBR green using the Bio-Rad MyiQ thermal
cycler with the following primers: Survivin (BIRC5, CAAG-
GAGCTGGAAGGCTGG and
GTTCTTGGCTCTTTCTCTGTCC), Cyclin D1 (CCND1:
GGATGCTGGAGGTCTGCGA and TAGAGGCCACGAA-
CATGCAAGT), and b2-microglobulin (B2M: GACTTTGTCA-
CAGCCCAAGATAG and TCCAATCCAAATGCGG-
CATCTTC).
Western Blot. Huh7 cells (56105) were cultured in DMEM+
10%FBS in 100 mm tissue culture dishes for 72 h. After change
with fresh medium, the cells were treated with 0, 2.5, 5, and
10 mM of FH535 for 38 h. DMSO (,0.1%) were used as vehicle
control. Protein concentrations in the cell extracts were assayed
with micro BCA protein assay kit according to provider’s protocol
(Thermo Scientific Pierce, Rockford, IL, USA). Specific antibodies
were obtained from Cell Signaling Technology (Danvers, MA,
USA). Western Blot band density was assayed with NIH ImageJ
software (Bethesda, Maryland, USA), and normalized by b-actin.
All the other procedures were performed as previously described
[25].
2.8 Statistical analysis
All analyses were performed using the software SPSS version 20
(International Business Machines Corporation, Endicott, NY,
USA). Data are presented as mean 6 SE. One-way ANOVA
followed by Tukey correction was used to compare means. The
level of statistical significance was set at p,0.05.
Results
3.1 FH535 inhibits transcriptional activation mediated by
wild-type and constitutively active b-catenin
FH535 has been shown to block signaling through endogenous
b-catenin in several cell lines, including the hepatoblastoma cell
line HepG2 [15]. To further explore this regulation and to test
whether FH535 could block ectopic b-catenin, co-transfections
with b-catenin expression vectors and the TCF4-dependent
luciferase reporter vector TOPFlash were performed in the
human HCC cell lines Huh7 and Hep3B (Fig. 1). In both cell
lines, co-transfected wild-type b-catenin expression vector in-
creased luciferase activity from TOPFlash nearly 15-fold com-
pared to cells co-transfected with the empty vector (E.V.) control.
This b-catenin-dependent increase was inhibited by FH535 in a
dose-dependent manner. b-catenin is often mutated in various
cancers, including HCC. One natural mutation changes the serine
at position 37; this altered form of b-catenin is resistant to
degradation by the APC complex and thus has higher stability. To
test whether this form of activated form of b-catenin could also be
blocked by FH535, an expression vector for bCatS37A, in which
the serine at position 37 has been changed to an alanine, was co-
transfected with TOPFlash. As expected, bCatS37A-mediated
transactivation of TOPFlash was significantly higher than
transactivation by wild-type b-catenin. However, in both cell
lines, bCatS37A-mediated transactivation was significantly inhib-
ited by FH535. As controls, cells were also co-transfected with
FOPFlash, which is identical to TOPFlash except that the TCF4
sites have been mutated and therefore no longer responsive to b-
catenin; FOPFlash was not activated by wild-type b-catenin or
bCatS37A as shown in Figure 1.
TOPFlash contains three consensus TCF4 binding motifs that
confer responsiveness to b-catenin. To test whether FH535 could
also block b-catenin-mediated transactivation of a TCF4 motif in
the context of a natural regulatory region, co-transfections were
performed with E3-pGL3. E3 is a ,340 bp fragment that contains
alpha-fetoprotein (AFP) enhancer element E3, one of three
enhancers that control hepatic expression of the mouse AFP gene.
E3 contains binding sites for multiple factors, including Foxa/
HNF6, C/EBP, orphan nuclear receptors, and TCF4 [26–27]. We
recently showed that this enhancer is regulated by b-catenin in
cells and transgenic mice [21]. E3-pGL3 was transactivated by b-
catenin and to a greater extent by bCatS37A (Fig. 1). However,
this transactivation by both wild-type and S37A forms of b-catenin
was blocked by FH535 in a dose-dependent manner.
3.2 FH535 inhibits b-catenin-mediated transcriptional
activation in LCSC
Previous studies have shown that b-catenin signaling is elevated
in EpCAM positive cells with LCSC properties [28]. We
previously described that CD133+, CD44+, CD24+ LCSC
aggressively form tumors when small numbers of these cells are
injected into nude mice [29]. To test the ability of FH535 to
inhibit b-catenin in these LCSCs, transient transfections were
performed with TOPFlash. As controls, TOPFlash was also
transfected into the HCC cell lines Huh7 and PLC (Fig. 2). In all
three populations, untreated cells exhibited low luciferase levels.
When treated with the GSK-3b inhibitor LiCl, which leads to
endogenous b-catenin activation [30], TOPFlash activity in-
creased dramatically. FH535 effectively blocked LiCl-mediated
Wnt/b-Catenin Signaling Pathway in HCC
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activation of TOPFlash in a dose-dependent manner. Interesting-
ly, this inhibition was more robust in LCSC than in either HCC
cell line. As a control, transfections were also performed with
FOPFlash, which is no longer responsive to b-catenin. As
expected, luciferase activity in FOPFlash-transfected cells was
neither increased by LiCl nor inhibited by FH535.
3.3 FH535 inhibits proliferation of LCSC and HCC cell
lines
Numerous studies have demonstrated that b-catenin plays an
important role in proliferation during normal development and in
cellular transformation in many tissues, including the liver. Liver
development is impaired in the absence of b-catenin, and
mutations that activate the b-catenin pathway are found in about
1/3 of HCC [4-5]. Furthermore, the growth of adult liver
progenitor stem cells (oval cells) can be inhibited by blocking the b-
catenin pathway. Since our data indicated that FH535 can block
b-catenin-mediated transcriptional activation, we also tested
whether proliferation of LCSC and HCC cell lines was affected
by this compound. LCSC were cultured in the presence of 10% or
1% serum and with between 5 mM and 30 mM FH535 for
72 hours, and cell proliferation was monitored by 3H-thymidine
incorporation (Figs. 3A and 3B, respectively). Proliferation
decreased with increasing amounts of FH535, with a more
dramatic reduction observed in cells grown in the presence of
lower serum; the concentration of FH535 to cause a 50%
inhibition of cell grown (IC50) was 13.8 mM for cells grown in 10%
serum and 5.1 mM for cells grown in 1% serum. This inhibition
was more potent than that seen with XAV939 (IC50 = 55 mM),
which inhibits tankyrase, thus stabilizing axin and promoting b-
catenin degradation (Fig. 3C) [31]. FH535 also blocked prolifer-
ation of HCC cells at concentrations that were similar to that seen
with LCSC (IC50 of 10.9 mM, 9.25 mM and 6.6 mM for Huh7,
PLC and Hep3B, respectively; Fig.3D). To confirm that FH535
indeed inhibited cell proliferation and did not lead to increased cell
death, FH535 and 3H-thymidine were added simultaneously to
Huh7 cells, which were then cultured for 18 h. In this scenario, we
observed a significant inhibition of proliferation at 2.5, 5, 10 and
15 mM of FH535 treatment as compared to control (p,0.05,
n = 6), with FH535 at 15 mM causing a 41% inhibition (Figure S3).
This data indicates that FH535 is inhibiting cell proliferation
rather than increasing cell death.
3.4 FH535 induces cell cycle arrest in the HCC cell line
Huh7 and in LCSC
The ability of FH535 to inhibit cell proliferation prompted us to
investigate the cell cycle distribution following treatment. Huh7
cells were synchronized by growth in 0.1% FBS for 24 hours and
Figure 1. FH535 inhibits b-catenin dependent transcriptional activation in HCC cell lines. Huh7 (Panel A) and Hep3B (Panel B) HCC cells
were transfected with the luciferase reporter genes TOPFlash (left panels), which contains three TCF binding sites, or E3-pGL3 (right panels), which
contains the AFP enhancer element E3 that has a highly conserved TCF site. Cells were additionally co-transfected with an expression vector that
contained no insert (empty vector control, E.V.), wild-type b-catenin (b-catenin), or a constitutively active form of b-catenin (bcatS37A). Renilla
luciferase was used to control for variations in transfection efficiency. Six hours after the addition of DNA, cells were treated with DMSO alone (no
treatment) or increasing amounts of FH535. After 48 hours, luciferase levels were determined; firefly luciferase was normalized to renilla. In both cell
lines, FH535 inhibited b-catenin-dependent activation of target genes. * P,0.05. The experiment was done twice with similar results.
doi:10.1371/journal.pone.0099272.g001
Wnt/b-Catenin Signaling Pathway in HCC
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Figure 2. FH535 inhibits TOPFlash activation in LCSC and HCC cell lines. LCSC (left panel), Huh7 (middle panel) and HPLC (right panel) cells
were co-transfected with TOPFlash or FOPFlash luciferase reporter genes along with renilla luciferase. After 6 hours, cells were left untreated (no
treatment) or treated with LiCl alone or LiCl with increasing amounts of FH535. LiCl is a known activator of b-catenin. After an additional 36 hours,
cells were harvested and luciferase levels were determined; firefly luciferase was normalized to renilla. TOPFlash activity was highly induced in all
three cell populations; this activation was inhibited by FH535. The negative control FOPFlash showed minimal response to LiCl or FH535. TOPFlash
inhibition by FH535 was more robust in LCSC than in either HCC cell line. * P,0.003, # P,0.001. The experiment was done twice with similar results.
doi:10.1371/journal.pone.0099272.g002
Figure 3. FH535 inhibits proliferation of LCSC and HCC cell lines. Cells were seeded in 96-well plates in 0.2 ml of media as described below
for 72 hours, followed by the addition of 3H-thymidine at 1 mCi/well for 4 hours. Incorporation of 3H-thymidine was determined by scintillation
counting. In panels A, B and D, the final concentration of DMSO in each well was 0.05%; in panel C, the final DMSO concentration in each well was
0.1%. (A) LCSCs were plated at 1000 cells/well in DMEM with 10% FBS along with DMSO alone or with increasing amounts of FH535. (B). LCSCs were
plated at 5000 cells/well in DMEM with 1% FBS with DMSO alone or with increasing concentrations of FH535. (C). LCSCs were plated in DMEM with
10% FBS at 1000 cells/well with DMSO alone or increasing concentrations of XAV939. (D). Huh7, Hep3B and PLC cells were plated in DMEM with 10%
FBS at 1000, 2500, and 5000 cells/well, respectively, with DMSO alone or increasing concentrations of FH535. P values are for all the three cell lines
treated with FH535 are compared to controls. The experiment was done twice with similar results.
doi:10.1371/journal.pone.0099272.g003
Wnt/b-Catenin Signaling Pathway in HCC
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then cultured in the presence of 10% FBS and with no FH535 or
FH535 at 7.5 mM and 15 mM. After 24 hours, cells were harvested
and DNA content was analyzed by propidium iodide staining. In
the presence of FH535, there was a statistically significant increase
in the number of cells in G0/G1 and a corresponding decreased in
the percentage of cells in S phase compared to cells grown in the
absence of FH535 (Fig. 4A). The number of cells in G2 was not
significantly altered by FH535. In addition, there was no sub-G1
peak detected by flow cytometry, indicating that FH535 was not
promoting apoptosis at the concentrations being use (see Figure
S4). We also did cell cycle analysis in LCSC after FH535
treatment and found FH535 at 15 mM significantly caused G1
phase arrest in LCSC (P = 0.012). FH535 also significantly
reduced G2/M phase in the LCSC after 24 h of 7.5 mM and
15 mM FH535 treatment (P = 0.038 and P,0.001 respectively), no
significant S phase inhibition was observed in LCSC (p = 0.446)
(Fig. 4B.). Our data are similar to previously published results and
reflects b-catenin regulation of cell cycle is different in different cell
types [32–33]. Cell cycle regulators (cyclins, CDKs and regulators)
can vary in different cell types, which could lead to different
responses after FH535 treatment. This may worth exploring in our
future study.
Figure 4. FH535 alters cell cycle progression in Huh7 and LCSC cells. A. Huh7 cells were cultured in DMEM +10%FBS for 24 h. The cells were
washed with serum free DMEM 3 times, then cultured in DMEM +0.1% FBS for 24 h for cell synchronization. Cells were then cultured in DMEM+10%
FBS along with different concentrations of FH535 for 24 h. The cells were harvested and stained with propidium iodide (PI) and analyzed by flow
cytometry according to the GenScript protocol (Piscataway, NJ, USA). Treatment with FH535 increased the percentage of cells in G1 and decreased
the percentage of cells in S phase. The experiment was done twice with similar results. B. LCSC cells were cultured in CelProgen complete LCSC
culture medium for 24 h. Cells were then washed with serum free CelProgen medium 3 times and cultured in CelProgen Medium +0.1% FBS for 24 h
for synchronization of the cells. The cells were then returned to CelProgen Complete Medium +10% FBS with different concentrations of FH535 for
24 h. Cell cycle was assayed as per Huh7 described above.
doi:10.1371/journal.pone.0099272.g004
Wnt/b-Catenin Signaling Pathway in HCC
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3.5 Expression of b-catenin target genes cyclin D1 and
Survivin is inhibited by FH535
b-catenin controls cell proliferation and survival by regulating
the expression of numerous targets genes. Two well-established
targets are the genes encoding Survivin (Birc5) and Cyclin D1
(CcnD1). Survivin is an anti-apoptotic protein that also regulates
progression through mitosis [34]; Cyclin D1 controls proliferation
by activating the G1 kinases cdk4 and cdk6 [35]. Survivin and
Cyclin D1 transcription are regulated through TCF elements in
their promoter regions [36]. To test whether FH535 inhibits
expression of these two b-catenin target genes, real-time RT-PCR
was performed with LCSC and HCC cells that were treated with
increasing amounts of FH535. Cyclin D1 and Survivin mRNA
levels were reduced by FH535 in all three cell populations in a
dose-dependent manner (Fig. 5). To confirm that this reduction in
mRNA levels also led to lower protein levels, western analysis was
performed using whole cell extracts from Huh7 cells. Both Cyclin
D1 and Survivin protein levels were reduced in a dose-dependent
manner, with the greatest reduction seen in the presence of 10 mM
FH535 (Fig. 6.). Densitometric analysis indicated that FH535 at 5
and 10 mM inhibited Cyclin D1 28% and 64% respectively;
FH535 at 5 and 10 mM inhibited surviving 24% and 48%
respectively (Fig. 6).
Discussion
In recent years, numerous signaling pathways have been
implicated in hepatic carcinogenesis. The b-catenin pathway is
essential in stem cells for self-renewal and maintenance of stem cell
properties. Disruption of this balance results in both genetic and
epigenetic changes, found in many cancers, including colon cancer
and HCC [4]. In this study, we used FH535 as an inhibitor of the
b-catenin pathway. This compound has been used previously to
inhibit b-catenin expression in cells from colon and lung as well as
in cells from hepatoblastoma and HCC [15]. In this report, the
authors concluded that FH535 was toxic to a number of cell lines,
including Huh7. However, their assays could not distinguish
between toxicity and reduced cell proliferation. Our data indicates
that FH535 does indeed inhibit cell proliferation; we did not
directly measure toxicity.
FH535 inhibition of LCSC proliferation is of interest due to its
potential therapeutic effect in chemo-resistant HCC. Our group
and others have focused on strategies to inhibit the proliferation of
LCSC and differences in resistance patterns with non-liver cancer
stem cell lines in vitro and in vivo.
Despite numerous efforts, the etiology of HCC tumorigenesis,
whether transformed cells originate from mature hepatocytes or
stem/progenitor cells remains unclear. Stem cells are defined by
their potential for self-renewal and by their ability to proliferate
and differentiate into diverse cell types [37]. In recent years,
studies have provided convincing evidence that these cells do exist
in solid tumors of many types including, brain, breast, colorectal,
liver, pancreas and prostate cancers [27]. In this study we have
used LCSC that are 64.4%, 83.2%, 96.4% and 96.9% positive,
respectively, for CD133, CD44, CD24 and Aldehyde A1 as
determined by flow cytometry. These cells have been previously
profiled not only by checking the LCSC markers but also by
evaluating their tumorigenic potential using low cell numbers
(using 2000 LCSCs instead of 100,000 HCC cells to generate
tumors) and studying resistance to several drugs. We previously
found that these LCSC have intermediate to high resistance to
drugs compare to non- liver cancer stem cell lines using different
inhibitors.
In this study, we found that FH535, LCSC inhibition of
proliferation was affected by FBS concentration in the culture
medium, suggesting that the PPAR pathway may be involved in
LCSC proliferation as found in the human cancer cell line
HCT116 [15]. This could be explained by a variety of fatty acids
and their derivatives present in the FBS that are natural agonists to
PPAR. It is possible the PPAR agonists suppress the inhibitory
effects of FH535 in cell culture. Indeed, in HCT116 cells, FH535
inhibition of b-catein/TCF-dependent luciferase reporter genes
was five times stronger in serum-free medium than in media
containing 10% FBS. The ability of FH535 to inhibit tumor
growth was dramatically increased when 10% FBS was replaced
with 10% BSA [15]. Lysophosphatidic acid was found to be an
effective PPAR agonist that could reverse FH535 induced
inhibition of HCT116 growth [15]. However, the potential
function of PPAR in LCSC is beyond the scope of this study
and needs further investigation. Recently, FH535 was found to be
the most potent drug among several other Wnt/b-catenin
inhibitors on human biliary tract cancer cells cultured in serum-
free medium [38]. Our study found that FH535 is much more
potent than XAV939 in 10%FBS DMEM. This may be related to
the PPAR inhibition potential of FH535. Our study found that
FH535 inhibited HCC cell lines Huh7, Hep3B and PLC
proliferation, indicating that Wnt/b-catenin signaling plays an
important role not only in LCSC but also in HCC.
Figure 5. FH535 reduces cyclin D1 and survivin mRNA levels in
LCSC and in HCC cell lines. LCSCs, Huh7 and Hep3B cells were
treated with DMSO alone or increasing concentrations of FH535 for
38 hours prior to harvesting. RNA was analysed by real-time PCR for
expression of Cyclin D1 (Panel A) or Survivin (Panel B). In both cases,
mRNA levels were plotted relative to b2-microglobulin. The experiment
was done twice with similar results.
doi:10.1371/journal.pone.0099272.g005
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FH535 inhibition of LCSC and HCC proliferation was
illustrated by its ability to inhibit b-catenin/TCF/LEF-dependent
luciferase reporter activity. To our knowledge, this is the first
report on the ability of FH535 to inhibit b-catenin/TCF/LEF
activity in LCSC and in HCC cell lines. Previously, Handeli and
Simon reported that FH535 inhibits b-catenin/TCF/LEF activity
in the HepG2 cell line, which was mistakenly labeled as HCC by
these authors [15]. For over thirty years this cell line was
considered HCC by numerous investigators. Lopez et al., who
initially isolated these cells, recently concluded that HepG2 cells
should in fact be considered a hepatoblastoma cell line [39].
Further studies will be needed to investigate how FH535 inhibition
of b-catenin influences LCSCs and HCCs. As shown here, cyclin
D1 and Survivin expression are inhibited by FH535. Survivin is an
anti-apoptotic protein that also regulates progression through
mitosis [26], whereas Cyclin D1 controls proliferation by
activating the G1 kinases [35]. Real-time RT-PCR and Western
analysis confirmed that the expression of these target genes was
evident at the mRNA and protein level. Our preliminary data
indicate that FH535 treatment does not alter CD133, CD13 and
EPCAM expression in LCSC and HCC cell lines (data not shown).
Further analysis of these and other stem cell markers are
warranted.
In conclusion, our data show that FH535 is a potent inhibitor of
the Wnt/b-catenin pathway in LCSCs and HCC cell lines.
Whether its ability to inhibit PPAR also affects the growth of
LCSCs and HCC cells will require further investigation. Further
studies will also be needed to investigate the in vivo efficacy and
toxicity of FH535 on HCC xenografts in an animal model. The
role of combination therapy using FH535 with other anti-HCC
Figure 6. FH535 reduces cyclin D1 and Survivin protein levels in Huh7 cells. Huh7 cells were treated with DMSO alone or increasing
amounts of FH535 for 38 hours prior to harvesting. Proteins were prepared, resolved by SDS-PAGE, and transferred for Western analysis with
antibodies against Cyclin D1, Survivin, and b-actin. The top of shows the western blot image; the bottom graph shows densitometric analysis of the
western data. This densitometric analysis indicated that FH535 at 5 and 10 mM inhibited Cyclin D1 protein levels 28% and 64% respectively; FH535 at
5 and 10 mM inhibited Survivin protein levels 24% and 48% respectively. The experiment was done twice with similar results.
doi:10.1371/journal.pone.0099272.g006
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drugs and the possibility of finding cross-talk of Wnt/b-catenin
pathway with other signaling pathways should be investigated.
Supporting Information
Figure S1 LCSC at passage 2 were used for flow cytometry
assays. Cells were washed with 16PBS and then treated with 2 ml
16 PBS + 0.12% EDTA in T25 flask and incubate at 37uC for
3 min. The cells were scraped to suspend with cell scraper.
Trypsin was not used to prevent degradation of CD133, CD44,
CD24 and ALDH markers. After centrifugation, the cells were
dissolved in 200ul of PBS +0.12% EDTA and FITC-conjugated
antibodies, (or negative control antibodies) were added at 1:500
dilution, followed by incubation at 30 min on ice. The stained and
unstained cells were then analyzed for CD133, CD44, CD24 and
ALDH using flow cytometry. FITC-CD133 antibody was from
Cel-Progen, FITC-CD44, FITC-CD24 and FITC-ALDH1 was
ordered from eBioscience (San Diego, CA, USA). In these LCSCs,
the CD133+ populations was 64.4% (A), the CD44+ population
was 83.2%, the CD24+ population was 96.4% and the ALDHA1+
population was 96.9% (D).
(TIF)
Figure S2 Female NOD/SCID mice (NOD.CB17-
prkdc‘SCID/NCrSD, 4–5 week old) were purchased from Harlan
Animal Research Laboratory (Indianapolis, IN, USA), housed and
maintained in our Division of Laboratory Animal Resources
animal facility. Mice received filtered air, sterile water and
irradiated food ad libitum. Tumors were generated by harvesting
first passage of LCSC cells (CelProgen Catalog number 36116-43,
San Pedro, CA) that were cultured in CelProgen Liver Cancer
Stem Cell Growth Media with Serum, from mid-log growth phase
and trypsinized with 0.05% Trypsin/EDTA (Invitrogen). Cells
were then washed and resuspended in a 50% mixture of Matrigel
(BD Biosceince, San Diego, CA, USA) in CelProgen Liver Cancer
Stem Cell Growth Media (serum free) to final cell number of
20,000 cells/ml. A volume of 0.1 ml of the cell suspension (2000
cells) was injected subcutaneously at the right flank of each mouse.
The mice were checked for tumor growth every other week and
mouse weight was measured. Tumors were found 28 days after
inoculation in all the 3 tested mice. When the tumor sizes reached
940–1020 mm3, the mice were euthanized by CO2. The tumors
were isolated and fixed in 10% Formalin for 48 h and
subsequently changed to 70% ethanol. The tumors were paraffin
embedded, cut to 5 mm sections and hematoxylin and eosin
stained for histological analysis. A: H&E 2006This photomicro-
graph depicts a tumor growing in sheets of disorganized,
haphazardly-oriented and pleomorphic cells that attest to its poor
differentiation. Brisk mitotic activity is present and areas of
necrosis are seen, implying rapid growth. B: H&E 4006 This
tumor is composed of cells with pleomorphic, vesicular nuclei that
have prominent nucleoli with occasional macronucleoli. There are
large numbers of mitoses, including abnormal forms with
quadripolar spindles, reflecting very high proliferative activity.
(TIF)
Figure S3 Huh7 cells were plated to 96 well plates at 2500 cells/
well in 0.1 ml culture medium and cultured for 24 h. The
following day, 3H-thymidine and varying concentrations of FH535
were added simultaneously to the designated wells and cultured for
18 h. 3H-thymidine incorporation was assayed as indicated in
Materials and Methods. *: p = 0.007 as compared to control; **:
p,0.001 as compared to control (n = 6).
(TIF)
Figure S4 Flow cytometry indicates that a sub-G1 peak is not
observed in Huh7 cells treated with FH535, indicating that FH535
does not increased apoptosis as judged by DNA fragmentation. A.
Control (DMSO alone). B. FH535 at 7.5 mM. C. FH535 at
15 mM.
(TIF)
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